Sixty-two cases of chondrosarcoma of bone were reviewed and histologically graded as low, medium or high-grade tumours. After excluding patients dead from unrelated causes or lost to follow-up, forty cases were available for ten-year follow-up and fifty-eight for five-year follow-up. The rates of survival, recurrence and metastasis were analysed according to the histological grading. Recurrence was further analysed according to the adequacy of treatment. The results were compared with those previously reported in the literature. There was a ten-year survival rate of 58 per cent. Recurrence developed in 58 per cent and was uncontrollable in 29 per cent. The recurrence rate was 87 per cent with inadequate treatment and 15 per cent with adequate treatment. Recurrences outside the limb bones usually proved uncontrollable; recurrences in the limb bones were amenable to further, and if necessary repeated, operations. High-grade chondrosarcoma had a metastatic risk of 75 per cent and eventual mortality of 88 per cent. Medium-grade chondrosarcoma had a metastatic risk of 14 per cent and a mortality of 60 per cent. Low-grade chondrosarcoma had a metastatic risk of 5 per cent and a mortality of 29 per cent.

Both laparoscopic and open repair are equally safe in the management of PPU. Our findings support the view that this procedure can be successfully used as a training operation.

2. Heatley MK, Maxwell P, Whiteside C, Toner PG. The diagnostic and prognostic value of the Ki67 antibody in breast disease. Mod. Pathol. 1994; 8; 889-890. 3. Heatley MK, Ewings P, Odling Smee W, Maxwell P, Toner PG. Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast. Pathology 2002; 34; 230-232. 4. Stewart RL, Royds JA, Burton JL, Heatley MK, Wells M. Direct sequencing of the P53 gene shows absence of mutations in endometrial adenocarcinomas expressing P53 protein. Histopathology 1998; 33; 440-445. 5. Burton JL, Stewart RL, Heatley MK, Royds JA, Wells M. p53 expression, p21 expression and the apoptotic index in endometrioid endometrial adenocarcinoma. Histopathology 1999; 35; 221-229.

No abstract

No abstract